Articles tagged with Drug Targets
Researchers have discovered a new oncogene, RET rearrangement, which is present in 15.7% of lung adenocarcinoma patients and may be targeted with existing tyrosine-kinase inhibitors. This finding presents a promising treatment option for patients with this specific mutation.
Researchers developed a novel approach to make ovarian cancer cells susceptible to an antitumor drug, potentially improving treatment outcomes. The strategy targets telomeres and shows promise in treating other epithelial cancers.
Two genetic mutations, PDGFRB and NOTCH3, have been identified as potential therapeutic targets for infantile myofibromatosis (IM), a rare and debilitating disorder. Current treatment options involve repeated surgical removal of tumors, which can be invasive and disfiguring.
Researchers successfully targeted doxorubicin to mitochondria, killing cancer cells even those with developed pumps. The study suggests this approach could work with other nucleus-targeting anti-cancer drugs.
Researchers have identified Dkk1 as a key player in the development of atherosclerosis, a condition that causes arteries to become stiff and narrow, leading to impaired blood flow. Targeting Dkk1 signaling may help limit arteriosclerotic disease, according to a new study.
A new osteoporosis treatment combination of denosumab and teriparatide was found to be more effective than individual therapies, increasing bone density in women with osteoporosis. The study showed significant improvements in BMD at the spine, hip, and femoral neck in women treated with the combination therapy.
Scientists from the University of Pennsylvania define a novel mechanism of tumor hypoxia induced by the longitudinal gradient of residual oxygen along tumor vessels as they transverse the tumor. The researchers found large regions of moderate hypoxia that were not easily explained by existing concepts, suggesting a new scale for unders...
Researchers at Scripps Research Institute discovered how to control natural gene silencing processes, leading to a powerful new class of drugs against viral infections, cancers and diseases. The study found that guide RNAs can be designed to destabilize or stabilize the miRNA-Argonaute complex.
Researchers have discovered a previously unknown link between over-stimulation and brain tissue destruction, pointing to a potential drug target. The study identified NOS1AP as the key protein that links nitric oxide production to cell damage.
Researchers have developed a new technique to improve the use of nanoparticles as a drug delivery system. The study found that smaller particles degrade faster in the body than predicted by in vitro measurements. By understanding this degradation, a mathematical model can be developed to optimize nanoparticle-based therapeutic systems.
Researchers used computer simulations to investigate the energy landscape of ion channels, identifying a critical amino acid that regulates their function. The study provides new insights into ion channel mechanisms, which are essential for developing targeted therapies.
A recent study reveals that a protein in our cells, responsible for transporting vital substances, also enables bacterial cells to develop resistance to antibiotics. This mechanism is linked to the development of antibiotic resistance and cancer drug resistance, highlighting the need for new therapeutic strategies.
Researchers at Duke Medicine found a biomarker produced by mast cells can predict severe dengue cases. Asthma drugs targeting mast cells also showed effectiveness in limiting vascular leakage associated with dengue infections.
BIND-014, a PSMA-targeted nanoparticle containing docetaxel, demonstrated anti-tumor activity in 28 patients with advanced or metastatic solid tumors. The Phase 1 trial showed encouraging signs of effectiveness, including one complete response and five patients with stable disease.
BIND-014, a targeted docetaxel Accurin candidate, demonstrated encouraging anti-tumor activity and was well-tolerated in 28 heavily-pretreated patients with advanced or metastatic solid tumors. The Phase 1 results established the maximum tolerated dose of 60 mg/m2 and showed signs of stable disease lasting at least four cycles.
Children with fragile X syndrome showed significant improvements in general behavior, anxiety, and mood-related behaviors after three months of minocycline treatment. The study provides evidence for the efficacy of minocycline as a targeted treatment for fragile X syndrome.
Researchers have mapped tapeworm genomes to identify potential drug targets using existing drugs, which could lead to faster and more effective treatments. The discovery has significant implications for the development of urgently needed therapies for these devastating diseases.
A phase IIa study suggests that ORM-12741, a new add-on drug, improves memory scores by 4% in individuals with moderate Alzheimer's disease, while worsening it by 33% in those receiving a placebo. The study found significant benefits in improving brain functions under stressful conditions.
A new study published in Biological Psychiatry found that antipsychotics with high binding affinity of alpha2 adrenergic and M1 muscarinic receptors are associated with a greater risk of stroke in elderly patients. The study also suggests that stroke risk is highest in the initial weeks of treatment and for those with higher daily doses.
The NEXT trial found biolimus stent to be non-inferior to everolimus stent in target-lesion revascularization and stent thrombosis rates at one year. The study's long-term data will determine if the device's disappearing polymer offers superior benefits over other available stents.
Researchers have discovered a single anti-ageing enzyme that can be targeted by all 117 tested drugs, leading to a new class of anti-ageing medications. The enzymes' activators, such as resveratrol, show promising results in trials for various diseases, including cancer, diabetes and Alzheimer's.
A comprehensive computer model of human metabolism has been developed, connecting the dots between the human genome and metabolism. The Recon 2 model advances understanding of human metabolism in health and disease, enabling identification of biomarkers and prediction of drug side effects.
Researchers identified a molecule called lipoxin A4 that plays a crucial role in resolving airway inflammation in asthma. This discovery provides new direction for developing next-generation asthma therapies to decrease chronic inflammation.
A new microscopy technique has allowed scientists to observe protein clusters in living cancer cells, enabling direct measurement of drug effects on target proteins. This breakthrough could significantly improve cancer treatment by reducing collateral damage associated with traditional therapies.
A novel screening method using genetically engineered baker's yeast identifies chemical compounds that target disease-causing parasites without harming human hosts. The approach has shown promise in identifying potential anti-parasitic compounds with high sensitivity, reducing costs, and increasing reproducibility.
A study reveals how daclatasvir, a hepatitis C drug, targets the NS5A protein and causes rapid viral decline. The research also provides an accurate estimate of the HCV half-life, revealing that the daily viral production is four times larger than previously thought.
Researchers suggest that a small number of cheap generic drugs can treat most non-communicable diseases (NCDs), improving availability in poorer nations. Better selection and sourcing of generics, as well as increased investment and policies, are key to making life-saving medicines affordable to all.
NIH researchers discovered a critical transport system in Staphylococcus aureus that produces deadly toxins, paving the way for new antibiotic treatments. The system, called Pmt, is thought to play a similar role in other staphylococci, such as S. epidermidis.
Researchers have identified a new mechanism by which the bladder senses its level of fullness through integrin proteins. This discovery may lead to the development of new drugs targeting this pathway to treat overactive bladder and incontinence.
Two new methods for detecting and measuring the levels of antisense drugs in cells have been developed, allowing researchers to track PMO delivery to individual cells and quantify its presence in tissue. These methods will advance the field of PMO research and provide valid alternatives to current time-consuming detection techniques.
Researchers at VCU have discovered a new way to customize and target antipsychotic drugs to treat specific symptoms in psychosis patients. By targeting G-protein receptor complexes, they aim to reduce side effects and improve treatment outcomes.
IRHOM2 is a protein that regulates TACE on immune cells, and blocking it could provide an effective treatment for rheumatoid arthritis. Researchers found that mice deficient in IRHOM2 were protected from inflammatory arthritis.
A new study found that metabolic stress can increase the onset of atrial arrhythmias, such as atrial fibrillation, by activating KATP channels in the atria. Blocking these channels with anti-diabetic drugs reversed the effects of metabolic stress and prevented atrial arrhythmia induction.
A team of researchers at the University of Pennsylvania School of Medicine discovered that metformin suppresses glucagon's ability to generate a signaling molecule, pointing to new drug targets. This finding could lead to improved diabetes treatments with reduced side effects.
Researchers have sequenced the genome of Pneumocystis jirovecii, a fungus that causes pneumocystis pneumonia, a common and often deadly infection in immunocompromised individuals. The genome reveals surprising facts about the pathogen's survival and virulence.
Researchers say targeting extraoral taste receptors in the gut could release hormones that signal fullness, mimicking meal effects and aiding weight loss. Additional studies are needed to identify effective drug targets for obesity treatment.
Researchers developed a novel approach to deliver cholesterol-conjugated small interfering RNAs (siRNAs) to liver cells using an endosomolytic polymer. The method significantly improves siRNA efficacy for targeted gene silencing, opening new possibilities for disease treatment.
Researchers have identified a new drug target, 4'-Phosphopantetheinyl Transferase PptT, which is essential for Mycobacterium tuberculosis (Mtb) growth and survival. This discovery offers hope for the development of new TB treatments that can shorten treatment duration and combat drug-resistant strains.
Researchers found that microRNA-218 is low in medulloblastoma patients and its addition stops disease occurrence. The microRNA also affects genes involved in tumor growth and migration, offering potential targets for therapy.
Recent advancements in lung cancer treatment focus on targeting specific genetic mutations, resulting in improved patient response rates (70-80%) compared to traditional chemotherapies. However, challenges remain in securing funding for clinical trials and staying ahead of the disease's rapid mutation rate.
Gladstone researchers propose targeting ApoE4 as a new strategy for treating Alzheimer's disease. They suggest that drugs can correct the shape of the ApoE4 protein, slowing or stopping its progression.
The growing US population and increased life expectancy necessitate new approaches to prostate cancer treatment. Researchers are exploring targeted therapies, immunotherapy, and precision radiation targeting to improve treatment outcomes for older patients.
GSK3-beta activates BACE1, producing amyloid beta that forms plaques, killing neural cells. Disabling GSK3-beta reduces plaque formation and improves memory in mice. A promising target for AD drug research, but its indiscriminate effects pose challenges.
Researchers have discovered how two proteins regulate telomeres, the protective caps on chromosome ends. The POT-1/TTP-1 complex promotes telomerase activity, a key target for anti-cancer drugs.
A recent study found that male malaria parasites can adapt faster to their surroundings, making them harder to treat. Targeting the slower-reproducing female parasites could lead to more effective long-term treatments and prevent parasite breeding.
Researchers discover Arih2 gene essential for immune system function, potentially leading to treatment breakthroughs for chronic infections like HIV and hepatitis. The gene's role in regulating the immune response could lead to new treatments that reinvigorate the immune system and help clear these infections.
Researchers have identified telomerase as a cause of chronic inflammation in human cancers, a key underlying factor for many diseases. Developing drugs to target this enzyme may lead to novel treatments that alleviate common ailments such as cancer and diabetes.
Researchers found that local ablative therapy and continuation of targeted drugs can prolong disease control by up to 6.2 months in patients with EGFR mutations or ALK rearrangements. The study's findings suggest a new approach to treating NSCLC after progression, particularly for patients with oligoprogressive disease.
Researchers at the University of Manchester have identified 14 new genes linked to rheumatoid arthritis, shedding light on why the condition disproportionately affects women. The study's findings could lead to personalized treatment approaches and improved disease management.
The UK BiLEVE study aims to discover the genes affecting lung function and susceptibility to COPD. Researchers will analyze data from 50,000 UK Biobank participants to identify genetic variants associated with COPD, shedding light on why some people are more prone to lung disease.
A new study published in CNS Drugs found that a single dose of etanercept can rapidly improve chronic neurological dysfunction caused by stroke or traumatic brain injury, even years after the event. The observational study involved 629 patients and documented positive effects on motor impairment, spasticity, cognition, and more.
Researchers at CU-Boulder have discovered a novel target for anti-cancer drug development by targeting the telomerase enzyme at the ends of chromosomes. This approach may provide an effective solution to the complex problem of cancerous cells. By blocking the telomerase enzyme, the growth of cancerous cells can be prevented.
Researchers at the University of Minnesota have developed a new drug called Minnelide to target and destroy tumor cells in pancreatic cancer. The drug works by inhibiting heat shock protein HSP 70, which aids tumor cell growth, effectively disintegrating the cancer.
Researchers at Moffitt Cancer Center have discovered new components of the DNA damage response network, including proteins that could be targeted as sensitizers for chemotherapy. The study's findings may lead to the development of new therapeutic strategies and accelerated treatment for cancer.
A large international study has identified 21 new gene variants associated with risks of heart disease and metabolic disorders. The findings expand the list of potential targets for drugs and other treatments for lipid-related cardiovascular disease, a leading global cause of death and disability.
A $20 million gift from Andrew and Barbara Taylor has established the Taylor Family Institute for Innovative Psychiatric Research at Washington University. The institute aims to develop new therapies for psychiatric disorders, which currently have major limitations in effectiveness and potential side effects.
Researchers have discovered smallest and fastest-known RNA switches, which could provide new targets for drug development. The newly found excited states of RNA molecules offer potential for disrupting HIV replication and interfering with protein assembly in bacterial ribosomes.
Researchers discovered that combining conventional antifungal medications with natural plant compounds, such as thymol, can inhibit the growth of fungi at lower doses. This could lead to more effective treatments for fungal infections, potentially even reducing economic losses from contaminated crops.
Researchers found Botox injections to be equally effective to oral medication in treating urinary urgency incontinence, with a higher proportion of complete resolution. The study also showed improved quality of life without significant differences.
Researchers at Wake Forest University have designed a targeted therapy that delivers a sneak attack on breast cancer cells, similar to a Trojan horse. The new platinum-based molecule has shown promising results in treating non-small cell lung cancer and pancreatic cancer, with potential applications for breast cancer treatment.